Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Sep 1;64(9):4921-4929.
doi: 10.1093/rheumatology/keaf231.

Indications, efficacy and safety of rituximab in childhood-onset systemic lupus erythematosus: a retrospective study of the JIR cohort

Jade Cognard  1 , Christine Pietrement  1 , Audrey Laurent  2 , Marine Fouillet-Desjonquères  2 , Patricia Moran-Alvarez  2 , Héloïse Reumaux  3 , Damia Leguevaques  3 , Yves Hatchuel  4 , Arthur Felix  4 , Pascal Pillet  5 , Charlotte Rebelle  6 , Diego Urbina  7 , Pierre Quartier-Dit-Maire  8 , Isabelle Melki  9 , Florence A Aeschlimann  8   10 , Isabelle Koné-Paut  11 , Linda Rossi-Semerano  11 , Micheline Pha  12 , Michaël Hofer  13 , Samira Plassart  2 , Brigitte Bader-Meunier  8 , Alexandre Belot  2
Affiliations

Indications, efficacy and safety of rituximab in childhood-onset systemic lupus erythematosus: a retrospective study of the JIR cohort

Jade Cognard et al. Rheumatology (Oxford). .

Abstract

Objectives: Childhood-onset systemic lupus erythematosus (cSLE) is a rare autoimmune disease with significant morbidity. Although B cell-depleting agents show promise for refractory cSLE, there is limited research on rituximab therapy in children. This study aimed to retrospectively assess the indications, efficacy, and safety of RTX in cSLE, using data from the Juvenile Inflammatory Rheumatism (JIR) cohort database.

Methods: A national retrospective study analysed data from the JIR cohort for cSLE patients treated with RTX from July 2009 to June 2023.

Results: Forty-one patients received RTX over 14 years; 85.4% were girls and mean age at diagnosis was 11.7 years. RTX was administered on average 16 months post-diagnosis. At treatment initiation, 87% either had received or were receiving corticosteroids, 21% NSAIDs and 82% immunosuppressants. Main indications for RTX were lupus nephritis (51.2%), persistent polyarthritis (19.5%) and refractory cytopenias (12.2%). Significant improvements in disease activity were observed at 3 and 6 months post-RTX infusion, indicated by the SLEDAI-2K score (P < 0.001), along with a notable reduction in corticosteroid usage (from 0.93 mg/kg to 0.39 mg/kg; P = 0.001) and improvements in relevant biomarkers. Adverse effects occurred in 17% of patients, with 7.3% experiencing anaphylactic reactions. One year following the last infusion, 52.5% of the paediatric subjects did not necessitate an increase in their baseline immunosuppressive therapy or the initiation of a novel treatment modality.

Conclusions: RTX in refractory cSLE reduced disease activity and steroid dependence with an acceptable safety profile. Further research and international collaboration are needed to validate these findings.

Keywords: B-cell depletion; cSLE; childhood-onset SLE; lupus; lupus nephritis; rituximab; safety; systemic lupus erythematosus; treatment.

PubMed Disclaimer